非活动性HBsAg携带者临床特征及自发性HBsAg血清学清除相关因素分析

肝脏 ›› 2020, Vol. 25 ›› Issue (2): 128-130.

• 病毒性肝炎 • 上一篇下一篇

非活动性HBsAg携带者临床特征及自发性HBsAg血清学清除相关因素分析

韦新焕, 张晶, 张卫, 柳雅立

100069 首都医科大学附属北京佑安医院丙型肝炎与中毒性肝病科(韦新焕,张晶,柳雅立);北京市疾病预防控制中心(张卫)

收稿日期:2019-11-18 出版日期:2020-02-29 发布日期:2020-03-26
通讯作者: 张卫,Email:zhangweipumc@163.com;柳雅立,Email:xxbi@163.com
基金资助:
北京市朝阳区艾滋病和病毒性肝炎等重大传染病综合示范区建设研究(2018ZX10715005-003-003);国家科技重大专项(十三五)(2017ZX10203202-002-06;2018ZX10721202);乙型肝炎联合治疗新方案对疾病远期转归的影响(2017ZX10202202-005-010)。

Clinical characteristics and related factors of spontaneous HBsAg seroclearance in inactive HBsAg carriers

WEI Xin-huan¹, ZHANG Jing¹, ZHANG Wei², LIU Ya-li¹

1. Beijing Youan Hospital, Capital Medical University, Beijing 100069, China;
2. Beijing Center for Disease Control and Prevention, Beijing 100013, China

Received:2019-11-18 Online:2020-02-29 Published:2020-03-26
Contact: ZHANG Wei, Email: zhangweipumc@163.com; LIU Ya-li, Email: xxbi@163.com

摘要/Abstract

摘要： 目的了解非活动性HBsAg携带者(inactive HBsAg carriers, IHC)临床特征及自发性HBsAg血清学清除相关因素。方法纳入2009年1月至2015年12月在北京佑安医院就诊且至少随访一次的IHC 289例,所有患者均未接受任何核苷类似物和(或)干扰素抗病毒治疗。将对随访过程中是否出现自发性HBsAg血清学清除患者进行差异比较。结果 289例IHC的ALT水平为(21.40±7.64)U/L,血清HBsAg、HBeAg、HBV DNA水平分别为4592.00 (2262.00,6741.00)COI、0.10 (0.09,0.12)COI和430.05 (213.25,824.25)IU/mL。血清HBsAg与HbeAg呈正相关(r=1.86,P<0.01),与年龄呈负相关(r=-1.82,P<0.01),与HBV DNA(r=0.09,P=0.58)无明显相关性。平均随访3年,其中17例(2.60%)患者发生自发性HBsAg血清学清除,年发生率为0.87%,其血清HBsAg、HBeAg、HBV DNA水平明显低于无自发性HBsAg血清学清除者(均P<0.01),而两组之间年龄、性别、肝功能等无明显差异。结论在IHC中,血清HBsAg与HBV DNA水平无明显相关性,血清HBsAg、HBeAg、HBV DNA水平较低者更易发生自发性HBsAg血清学清除。

关键词: 非活动性HBsAg携带者, HBsAg滴度, 自发性HBsAg血清学清除

Abstract: Objective To investigate the clinical characteristics and related factors of spontaneous hepatitis B surface antigen (HBsAg) clearance in inactive HBsAg carriers (IHCs). Methods IHCs in our hospital from January 2009 to December 2015 were enrolled and followed up at least once. None of the patients received any nucleoside analogues and/or interferon antiviral therapy. The differences between patients with and without spontaneous HBsAg clearance during follow-up were retrospectively analyzed. Results A total of 289 IHCs were enrolled in this study, including 161 males (55.71%) with an average age of 46.80 years. The alanine aminotransferase level was 21.40 ± 7.64 U/L, and serum HBsAg, hepatitis B envelope antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) levels were 4592.00 (2262.00-6741.00) COI, 0.10 (0.09-0.12) COI and 430.05 (213.25-824.25) IU/mL, respectively. Serum HBsAg level was correlated with HBeAg level (r=1.86, P<0.01) and age (r=-1.82, P<0.01), but had no relationship with HBV DNA (r=0.09, P=0.58). During an average follow-up of 3 years, 17 patients (2.60%) had spontaneous HBsAg serological clearance, with an annual incidence of 0.87%. The serum levels of HBsAg, HBeAg and HBV DNA in patients with spontaneous HBsAg serological clearance were significantly lower than those in patients without (all P<0.01), but there were no significant differences in gender, age and liver function between the 2 groups. Conclusion There is no significant correlation between serum HBsAg and HBV DNA levels in IHCs. Patients with lower serum levels of HBsAg, HBeAg and HBV DNA are more likely to achieve spontaneous HBsAg serological clearance.

Key words: Inactive hepatitis B surface antigen carrier, Hepatitis B surface antigen titer, Spontaneous hepatitis B surface antigen seroclearance

韦新焕, 张晶, 张卫, 柳雅立. 非活动性HBsAg携带者临床特征及自发性HBsAg血清学清除相关因素分析[J]. 肝脏, 2020, 25(2): 128-130.

WEI Xin-huan, ZHANG Jing, ZHANG Wei, LIU Ya-li. Clinical characteristics and related factors of spontaneous HBsAg seroclearance in inactive HBsAg carriers[J]. Chinese Hepatolgy, 2020, 25(2): 128-130.

参考文献

[1] Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology, 2010, 138: 1747-1754.
[2] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版).肝脏,2015,20:915-932.
[3] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018,67:1560-1599.
[4] Tong MJ, Trieu J. Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis,2013,14: 311-7.
[5] McMahon BJ.The natural history of chronic hepatitis B virus infection. Hepatology,2009,49(5 Suppl): S45-55.
[6] McMahon BJ.The natural history of chronic hepatitis B virus infection. Hepatology, 2009,49(5 Suppl): S45-S55.
[7] Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int, 2014, 34: 97-107.
[8] Alghamdi A, Aref N, El-Hazmi M, et al. Correlation between Hepatitis B surface antigen titers and HBV DNA levels. Saudi J Gastroenterol, 2013,19: 252-257.
[9] Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology, 2010,51: 1933-1944.
[10] Zhenhuan Cao, Yali Liu, Lina Ma, et al., A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology, 2017, 66:1058-1066.
[11] Yee Hui Yeo, Hsiu J.Ho, Hwai-I Yang, et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology, 2019,156: 635-646.
[12] Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology, 2010, 139:483-490.
[13] Su TH, Liu CJ, Tseng TC, et al. Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLos One, 2013,8: e55916.

相关文章 0

编辑推荐

Metrics

本文评价